UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934

April 20, 2010
Date of Report (Date of earliest event reported)

Acura Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)

(847) 705-7709
Registrant's telephone number, including area code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
	[   ]	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	[   ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	[   ]	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	[   ]	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 8.01. Other Events.

     On April 20, 2010 we issued a press release disclosing that the Food and Drug Administration has posted on its website briefing documents in connection with the joint meeting of the Anesthetic and Life Support Drugs and the Drug Safety and Risk Management Advisory Committees scheduled for April 22, 2010 relating to Acurox® (oxycodone HCl and niacin) Tablets. A copy of our press release is attached as Exhibit 99.1 hereto.

Item 9.01. Financial Statements and Exhibits.

Exhibit Number		Description
99.1		Press Release dated April 20, 2010

---

SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Acura Pharmaceuticals, Inc.
Date: April 20, 2010	By:	/s/   PETER A. CLEMENS Peter A. Clemens Senior Vice President & Chief Financial Officer

---

EXHIBIT INDEX

Exhibit Number		Description
99.1		Press Release dated April 20, 2010